(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 2 571 488 B2

(12) **NEW EUROPEAN PATENT SPECIFICATION**
After opposition procedure

(45) Date of publication and mention of the opposition decision:
26.07.2017 Bulletin 2017/30

(45) Mention of the grant of the patent:
18.06.2014 Bulletin 2014/25

(21) Application number: **11720479.2**

(22) Date of filing: **18.05.2011**

(51) Int Cl.:
A61K 9/10 *(2006.01)* ***A61K 31/19*** *(2006.01)*
A61K 47/18 *(2017.01)*

(86) International application number:
PCT/EP2011/058087

(87) International publication number:
WO 2011/144677 (24.11.2011 Gazette 2011/47)

(54) **PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION**

PHARMAZEUTISCHE ZUBEREITUNG ZUR INJEKTION ENTHALTEND IBUPROFEN

COMPOSITION PHARMACEUTIQUE POUR INJECTION COMPRENANT IBUPROFEN

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **18.05.2010 PCT/ES2010/070330**

(43) Date of publication of application:
27.03.2013 Bulletin 2013/13

(73) Proprietor: **Genfarma Laboratorio, S.L.**
28230 Las Rozas Madrid (ES)

(72) Inventors:
- **ORTÚZAR ANDÉCHAGA, Ignacio**
  E-28230 Las Rozas (Madrid) (ES)
- **ORTÚZAR GUTIÉRREZ, Mario**
  E-28230 Las Rozas (Madrid) (ES)

(74) Representative: **Elzaburu S.L.P.**
Miguel Ángel, 21, 2º
28010 Madrid (ES)

(56) References cited:
DE-A1- 19 912 436 **DE-A1- 19 912 436**

- **WANG T ET AL: "Increased levels of monohydroxy metabolites of arachidonic acid and linoleic acid in LDL and aorta from atherosclerotic rabbits", BIOCHIMICA ET BIOPHYSICA ACTA - LIPIDS AND LIPID METABOLISM, ELSEVIER SCIENCE BV. AMSTERDAM, NL, vol. 1084, no. 2, 9 July 1991 (1991-07-09) , pages 129-138, XP027222492, ISSN: 0005-2760 [retrieved on 1991-07-09]**
- **SOARES D M ET AL: "CCL3/Macrophage inflammatory protein-1alpha induces fever and increases prostaglandin E2 in cerebrospinal fluid of rats: Effect of antipyretic drugs", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1109, no. 1, 13 September 2006 (2006-09-13), pages 83-92, XP027538689, ISSN: 0006-8993 [retrieved on 2006-08-26]**
- **Scientific discussion for the approval of Pedea at the Europe Medicines Agency**
- **Tromethamine - The Merck Index.**
- **"Pedea (ibuprofen) Authorization details". European Medicines Agency Web. (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000549/human_med_000973.jsp, downloaded on 20.05.2016**
- **UNIVERSITY COLLEGE LONDON HOSPITALS. NHS. PHARMACY DEPARTMENT: 'Injectable Medicines Administration Guide', vol. THIRD ED, 2010, WILEY-BLACKWELL pages 51-59 - 198**
- **'Neonatal Formulary 5. Drug Use in Pregnancy and the First Year of Life', vol. FIFTH ED, 2007, BLACKWELL PUBLISHING deel 'Ibuprofen', page 126**
- **'Vademecum Internacional', vol. 49TH ED., 2008, MEDICOM page 2126**
- **'Rote Liste® 2008', 2008, HERAUSGEBER UND VERLAG ROTE LISTE SERVICE GMBH, FRANKFURT pages 53, - 067,**

Remarks:
The file contains technical information submitted after the application was filed and not included in this specification

EP 2 571 488 B2

Description

Field of the invention

[0001] The present invention relates to a pharmaceutical composition for intravenous use that comprises 2-(4-isobutylphenyl)-propionic acid (ibuprofen), trometamol and NaCl.

Background of the invention

[0002] 2-(4-Isobutylphenyl)-propionic acid (ibuprofen) is an analgesic, antipyretic, anti-inflammatory drug that has the following chemical formula:



[0003] Ibuprofen is a drug that has become very well known since its invention in the 1960s, and is currently marketed for the treatment of pain, inflammation and fever, under a variety of trade names in pharmaceutical forms for oral administration.

[0004] Ibuprofen can be in the form of the (R) or (S) enantiomers, and although it is the (S) enantiomer that is biologically active, the majority of preparations contain the racemic mixture, since the (R) enantiomer is converted to the active form (S) *in vivo*. Hereinafter, "ibuprofen" is to mean either of the two enantiomers, (R) or (S), or the racemate.

[0005] Despite its many advantages, one of the main drawbacks of ibuprofen is, however, its poor solubility in water. Ibuprofen is a monoprotic acid with pKa= 4.4. Its solubility is therefore closely related to pH, and may vary from 78 micrograms/mL at acidic pHs to 291 mg/mL at alkaline pHs. As a result, the development of certain dosage forms of ibuprofen, in particular liquid dosage forms for injection, has been problematic.

[0006] Thus, for example, international publications WO 03/039532 A1 and WO 2005/065674 A1 describe liquid pharmaceutical compositions of ibuprofen that include amino acids such as arginine for improving the solubility of ibuprofen, and that have pH values below 7.8. However, these formulations have the drawback that, although they can be submitted to thermal treatment up to a certain degree, they cannot be autoclaved since in the conditions of autoclave sterilization, i.e. generally for 15 minutes at 121°C, the arginine would decompose, generating unforeseeable impurities. This means that such formulations cannot be submitted to the aforesaid autoclaving procedure, which is the method of sterilization that must be used as first choice and is the most advisable for any injectable pharmaceutical formulation.

[0007] An injectable pharmaceutical composition of ibuprofen is already marketed with the trade name Caldolor, with composition according to the formulation described in the international publications cited above, and which is indicated for the treatment of moderate to severe pain and for fever. This formulation contains, per 1 mL of solution, 100 mg of ibuprofen in water for injection (therefore at a concentration of 100 mg/mL of ibuprofen) and 78 mg of arginine, at arginine:ibuprofen molar ratio of 0.92:1, in glass vials that contain 400 or 800 mg of ibuprofen, and at a pH of about 7.4. This formulation, however, is very concentrated for direct use and requires subsequent dilution to 100 or 200 millilitres. Moreover, as already mentioned, it cannot be autoclaved, thus necessitating very expensive aseptic manufacture.

[0008] Pharmaceutical formulations for parenteral use that contain ibuprofen at a concentration of 8 mg/mL and trometamol (tris-hydroxymethyl-aminomethane) at a concentration of 6.04 mg/mL, the pH being limited to the range 7.8-8.2, are also known from DE 199,12 436 A1 and its subsequent international publication WO 00/56325. However, this document neither describes nor suggests formulations with other values of concentration of the stated components, or with pH values outside of the stated range. In addition, the relatively high content of ibuprofen in the compositions disclosed in this document may compromise the solubility of ibuprofen at the pH of the composition, and the additional fact that the sterilization of these compositions was carried out by sterile filtration suggests that these compositions were possibly not suitable for sterilization in autoclave. This unsuitability has anyway been demonstrated through comparative experimental tests reported hereinbelow.

Summary of the invention

[0009] Accordingly, the problem to be solved by the present invention is to provide injectable liquid formulations of ibuprofen that overcome the drawbacks of the compositions disclosed in the prior art, and in particular that permit autoclaving with minimal loss of ibuprofen and production of impurities and other parameters of pharmaceutical interest

that remain within the acceptable limits in the pharmacopoeia after the autoclaving process. Although a certain number of formulations of ibuprofen are described in the prior art, there is, however, the difficulty that none of them can be autoclaved, as their formulation includes compounds that degrade during autoclaving, giving rise to unforeseeable impurities, which rules them out for use for injection.

[0010] The solution to this problem is based on the fact that the inventors have found that liquid compositions of ibuprofen in which this active principle is at a concentration of between 2 and 6 mg/mL, and preferably approximately 4 mg/mL, that comprise trometamol at a concentration of between 1.8 and 5.8 mg/ml and that have a pH from 8.0 to 9.0, surprisingly can be autoclaved with a minimal loss of active principle and a low increase of impurities that remain within acceptable limits, so that they are particularly suitable for use as an injectable pharmaceutical formulation. The aforementioned properties of these formulations, so that they can be autoclaved, displaying minimal loss of active principle and acceptable production of impurities after autoclaving, have been demonstrated in different types of containers, such as containers made of plastic such as polypropylene (PP), PVC or polyethylene, though also in glass containers, although to a varying extent in each of them.

[0011] Therefore a first aspect of the invention relates to a pharmaceutical composition of ibuprofen for injection that comprises an aqueous solution of ibuprofen and trometamol, in which the concentration of ibuprofen is between 2 and 6 mg/mL, and preferably about 4 mg/mL, the trometamol is at a concentration of between 1.8 and 5.8 mg/ml, and preferably about 3.8 mg/ml, and the pH of said composition is between: 8.0 and 9.0. These compositions are useful in the treatment of pain, inflammation or fever.

[0012] In a second aspect, the invention relates to the use of said compositions in the manufacture of a medicinal product for the treatment of pain, inflammation or fever.

Detailed description of the invention

[0013] The liquid pharmaceutical compositions of the invention therefore comprise ibuprofen at a concentration between 2 and 6 mg/ml, and preferably of about 4 mg/ml, trometamol at a concentration between 1.8 and 5.8 mg/ml, preferably about 3.8 mg/ml, and the necessary NaCl to provide suitable isotonicity that is usually about 300 mOsm/kg, which requires a concentration of NaCl preferably of about 7.7 mg/ml. It is believed that the trometamol aids in increasing the dissolution rate of ibuprofen in the aqueous solvent and also helps in maintaining the stability of ibuprofen in solution. In the compositions of the invention, the trometamol is added at a concentration of between 1.5 and 5.8 mg/ml, and preferably about 3.8 mg/ml. The pH of the compositions of the invention is between 8.0 and 9.0, and most preferably about 8.5, depending on the container in which they are presented. The pH can be adjusted by any means known by a person skilled in the art for carrying out said adjustment, although preferably it will be done with NaOH/HCl until the desired pH is reached.

[0014] Throughout the present specification, "autoclaving" means any thermal method that makes sterilization of the formulation possible, and in particular a procedure during which the formulations are submitted to a temperature between 110 and 130°C for a time of 2 to 190 minutes, and more particularly to a temperature between 120 and 125°C for a time of 15 to 20 minutes.

[0015] Also throughout the present specification, it will be understood that a solution for injection is sterilizable by heat or "autoclavable" when, after undergoing an autoclaving procedure according to the preceding paragraph, its content in ibuprofen is at least 95% of the initial ibuprofen content added to the solution.

Experimental tests

[0016] Various experimental tests of formulation and autoclaving of ibuprofen were carried out, in various packaging materials: polyethylene (PE), glass, polyvinyl chloride (PVC) and polypropylene (PP), at various pH values. In this connection, it must be pointed out that, throughout the present specification, when reference is made to the packaging material for the compositions of the invention, this is to be understood as the material that is in direct contact with said compositions. Obviously, the containers that contain the compositions according to the invention can be composed of layers of different materials, so that the layers that are not in direct contact with the compositions according to the invention can have a different composition from that indicated.

[0017] The formulation used was as follows:

- Ibuprofen base BASF: 4 mg/ml
- Trometamol Merck: 3.8 mg/ml
- NaCl Esco: 7.7 mg/ml

In order to prepare the compositions used in the following experimental tests, the excipients were first added to water at the temperature of 50°C. Then the ibuprofen was added under stirring, and after about one hour of stirring the ibuprofen

was completely dissolved. Finally, the pH was adjusted to the desired value using HC1 1N and/or NaOH 1N, depending on the case.

With this base formulation, samples were prepared at the following values of pH: 6.5, 7.0, 7.5, 7.8, 8.0, 8.2, 8.5, 9.0 and 9.5. Each of these formulations was packaged in glass containers, bags of polypropylene (PP), bags of PVC and containers of low density polyethylene. In the autoclaving tests, the glass containers, the polypropylene bags and the PVC bags were autoclaved at 121°C for 15 minutes, as specified by the conditions of the European Pharmacopoeia for this process. The polyethylene containers were autoclaved at 110°C for 3 hours. In parallel, a series of comparative compositions was prepared in the same conditions as the above but using the formulation disclosed in DE 199 12 436 A1, namely:

- Ibuprofen base BASF: 8 mg/mL
- Trometamol Merck: 6.05 mg/mL
- NaCl Esco: 5.4 mg/mL

In this case, the compositions were adjusted to the following pH values: 7.8, 8.2 and 9.0, and were tested only in 100 mL capacity containers of different materials.

[0018] The results obtained were as follows:

1) Investigation of the content of impurities in the test formulations after autoclaving:

[0019] Determination of impurities was carried out by analysis by HPLC using the following parameters:

Mobile phase: For preparation of the mobile phase, 3 ml of ammonia was dissolved in 1920 ml of water, adjusting to pH = 2.5 with phosphoric acid; then 1080 ml of acetonitrile was added.
Flow: 2.3 ml/min.
Column: C18, 150 mm x 4.6 mm, 5 μm.
Detection: 214 nm.
Volume injected: 10 μl.
Temperature = 25°C.
Duration = 40 minutes.
Test sample: Direct injection.
Reference sample: Standard solution of ibuprofen in mobile phase at a concentration of ,0.04 mg/ml (1.0% relative to the test sample).
Suitability solution: Contains 4 μg/ml of impurity B and 4 mg/ml of ibuprofen.
Suitability criterion: The resolution between ibuprofen and impurity B is greater than 2.

[0020] The results obtained for the various formulations in the various containers were as shown in the following tables, in which the impurities are indicated by their corresponding retention time (Trr) in the HPLC test and, when said impurity has been identified, they also show the letter (A, J, N, etc.) that defines said impurity according to the corresponding analysis certificate according to the European Pharmacopoeia:

- pH 6.5:

[0021]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	0.01	0.01	0.01	0.01
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02	0.02	0.01	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND	0.05	0.03	0.04	ND
Total	0.10	0.10	0.10	0.10	0.16	0.13	0.15	0.11

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	0.01	0.02
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.11	0.12

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	0.02	0.02
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.01	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.11	0.12

[0022] It can be seen that in the samples packaged in containers of glass and of PE, the total content of impurities changes, on average, from approximately 0.10% before autoclaving to 0.12% after autoclaving, whereas in those kept in containers of PVC and PP it changes from approximately 0.10% to 0.15%, and is in all cases below the reference value of 0.20%.

- pH 7.0:

[0023]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	0.01	0.01	0.01	0.01
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02	0.02	0.01	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND	0.06	0.04	0.03	ND
Total	0.10	0.10	0.10	0.10	0.17	0.14	0.14	0.11

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	0.02	0.02
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.12	0.12

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	0.02	0.02
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.12	0.12

[0024] Once again it can be seen that in the samples packaged in containers of glass and of PE, the total content of impurities changes, on average, from approximately 0.10% before autoclaving to 0.12% after autoclaving, whereas in those kept in containers of PVC and PP it changes from approximately 0.10% to 0.15%, and is in all cases below the reference value of 0.20%.

- pH 7.5:

[0025]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	ND	0.01	0.01	0.01
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND	0.05	0.03	0.04	ND
Total	0.10	0.10	0.10	0.10	0.15	0.13	0.15	0.11

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	0.01	0.01
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.11	0.11

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	0.02	0.02
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.12	0.12

[0026] It is also observed at this pH that, in the samples packaged in containers of glass and of PE, the total content of impurities changes from approximately 0.10% before autoclaving to 0.12% after autoclaving, whereas in those kept in containers of PVC and PP it changes from approximately 0.10% to 0.15%, and is in all cases below the reference value of 0.20%.

- pH 8.0:

[0027]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.01	0.02	0.02	0.01	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND	0.03	ND	0.03	ND
Total	0.09	0.10	0.10	0.09	0.13	0.10	0.13	0.10

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	0.01	0.01
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.11	0.11

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	0.01	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.11	0.10

[0028] In this case we observe a smaller increase in the resultant level of impurities after autoclaving, since, in the samples packaged in containers of glass and of PE, the total content of impurities changes on average from approximately 0.10% before autoclaving to 0.11% after autoclaving, whereas in those kept in containers of PVC and PP it changes on average from approximately 0.10% to 0.12%, and is in all cases below the reference value of 0.20%.

- pH 8.5:

[0029]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.02	0.01	0.02	0.01	0.02	0.02	0.02	0.01
0.93 (Imp A)	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND	0.02	0.03	0.04	0.01
Total	0.10	0.09	0.10	0.09	0.12	0.13	0.14	0.10

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.01	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.09	0.10	0.10	0.10

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.01	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.09	0.10	0.10	0.10

[0030] In the present case with pH 8.5, the trend already observed at pH 8.0 appears to be maintained, namely observation of a smaller increase in the level of impurities after autoclaving, since in the samples packaged in containers of glass and of PE, the total content of impurities changes, on average, from approximately 0.10% before autoclaving to 0.11% after autoclaving, whereas in those kept in containers of PVC and PP it changes on average from approximately 0.10% to 0.13%, and is in all cases below the reference value of 0.20%.

- pH 9.0:

[0031]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.06	0.01	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.06	0.02	0.02	0.02	0.02	0.03
1.83	ND	ND	ND	ND	0.01	ND	0.04	0.02
Total	0.10	0.10	0.18	0.09	0.11	0.10	0.14	0.13

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	ND	ND
0.31. (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.01
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.10	0.09

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.01	0.01	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.09	0.09	0.10

[0032] At pH 9.0 it appears that the previous trend is still maintained, since in the samples packaged in containers of glass and of PE, the total content of impurities remains practically constant after autoclaving, whereas in those kept in containers of PVC and PP it increases slightly, on average from approximately 0.10% to 0.12%, and is in all cases below the reference value of 0.20%.

- pH 9.5:

[0033]

Impurities (%)								
Trr	Without Autoclaving				Autoclaved			
	PVC 100 ml	PVC 200 mm	PP 100 ml	PP 200 ml	PVC 100 ml	PVC 200 ml.	PP 100 ml	PP 200 ml
0.20 (Imp J)	ND	ND	ND	ND	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
0.58	0.01	0.02	0.02	0.01	0.02	0.02	0.01	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND	0.01	ND	0.03	0.02
Total	0.09	0.10	0.10	0.09	0.11	0.10	0.12	0.12

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	Glass 100 ml	Glass 200 ml	Glass 100 ml	Glass 200 ml
0.20	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.01	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.09	0.10	0.10

Impurities (%)				
Trr	Without Autoclaving		Autoclaved	
	PE 100 ml	PE 200 ml	PE 100 ml	PE 200 ml
0.20 (Imp J)	ND	ND	ND	ND
0.31 (Imp N)	0.06	0.06	0.06	0.06
0.58	0.02	0.02	0.02	0.02
0.93 (Imp A)	0.02	0.02	0.02	0.02
1.83	ND	ND	ND	ND
Total	0.10	0.10	0.10	0.10

[0034] Again at pH of 9.5, the samples packaged in containers of glass and of PE show a practically unchanged content of impurities after autoclaving, whereas those packaged in containers of PVC and PP show, after said process, a smaller increment than at the previous pH values, changing on average from 0.10% to 0.11%.

[0035] Accordingly, it can be concluded that, after the autoclaving process, the increase in the content of impurities is smaller as the pH increases, which undoubtedly means an appreciable advantage for formulations intended for use in injection.

2) Investigation of the ibuprofen content of the test formulations after autoclaving:

[0036] Without ignoring the relevance of other parameters such as the content of impurities, it is beyond doubt that for a pharmaceutical compositon for injection the content of ibuprofen after autoclaving is a very important parameter. For the present purposes, the minimum acceptable content of ibuprofen after autoclaving is considered to be at least 95% of the initial ibuprofen content added to the solution.

[0037] After autoclaving, the ibuprofen remaining in the formulations was determined by evaluating the loss produced by the autoclaving. Determination of ibuprofen was again based on analysis by HPLC using the following parameters:

Mobile phase: For preparation of the mobile phase, 6 g of trifluoroacetic acid was dissolved in 600 ml of water and was adjusted to pH = 3 with dilute ammonium hydroxide; then 900 ml of acetonitrile was added.
Flow: 1 ml/min.
Column: C18, 150 mm x 4.6 mm, 5 μm.
Detection: 254 nm.
Volume injected: 10 μl.
Temperature = 25°C.
Duration = 8 minutes.
Test sample: The test sample of ibuprofen is diluted to a concentration between 0.8 and 1.0 mg/ml.
Reference sample: Standard solution of ibuprofen in mobile phase at a concentration between 0.8 and 1.0 mg/ml.

[0038] The results are shown in the following table:

pH	Material	Volume	Ibuprofen content % on 4 mg/ml (before autoclaving)	Ibuprofen content % on 4 mg/ml (after autoclaving)	Variation in the ibuprofen content (%)
6.5	PVC	100 ml	101.8	83.6	-17.9%
		200 ml	101.0	85.2	-15.6%
	PP	100 ml	100.9	94.0	-6.8%
		200 ml	102.6	97.6	-3.3%
	Glass	100 ml	102.7	92.0	-10.4%
		200 ml	101.6	93.5	-8.0%
	PE	100 ml	100.3	94.5	-5.8%
		200 ml	99.8	96.4	-3.4%
7.0	PVC	100 ml	102.8	89.8	-12.6%
		200 ml	103.2	93.6	-9.3%
	PP	100 ml	103.0	97.9	-5.0%
		200 ml	101.0	99.4	-1.6%
	Glass	100 ml	102.0	103.3	+1.3%
		200 ml	103.4	104.1	+0.7%
	PE	100 ml	100.7	100.8	+0.0%
		200 ml	102.2	102.2	+0.0%
7.5	PVC	100 ml	104.6	97.8	-6.5%
		200 ml	102.6	99.0	-3.5%
	PP	100 ml	103.7	104.2	+0.5%
		200 ml	103.9	103.9	+0.0%
	Glass	100 ml	102.7	101.5	-1.2%
		200 ml	100.8	101.2	+0.4%
	PE	100 ml	102.3	98.9	-3.3%
		200 ml	102.1	103.3	+1.2%
7.8	PVC	100 ml	102.1	97.9	-4.1%
	PP	100 ml	102.7	99.4	-3.2%
	Glass	100 ml	103.1	102.7	-0.4%
	PE	100 ml	102.2	100.2	-2.0%
8.0	PVC	100 ml	101.1	99.7	-1.4%
		200 ml	99.2	99.6	+0.4%
	PP	100 ml	100.8	95.9	-4.9%
		200 ml	100.2	102.4	+2.2%
	Glass	100 ml	102.9	104.7	+1.7%
		200 ml	102.3	101.6	-0.1%
	PE	100 ml	100.6	103.9	+3.3%
		200 ml	102.5	103.4	+0.9%

(continued)

pH	Material	Volume	ibuprofen content % on 4 mg/ml (before autoclaving)	Ibuprofen content % on 4 mg/ml (after autoclaving)	Variation in the ibuprofen content (%)
8.2	PVC	100 ml	102.5	99.1	-3.3%
	PP	100 ml	102.0	100.5	-1.5%
	Glass	100 ml	102.5	99.1	-3.3%
	PE	100 ml	102.1	100.8	-1.3%
8.5	PVC	100 ml	102.0	102.3	+0.3%
		200 ml	101.2	103.0	+1.8%
	PP	100 ml	101.9	103.7	+1.8%
		200 ml	102.1	102.3	+0.2%
	Glass	100 ml	101.1	101.1	+0.0%
		200 ml	101.1	101.4	+0.3%
	PE	100 ml	100.7	101.6	+0.9%
		200 ml	101.4	101.1	-0.3%
9.0	PVC	100 ml	103.4	103.4	+0.0%
		200 ml	101.3	103.6	+2.3%
	PP	100 ml	103.5	103.9	+0.4%
		200 ml	100.2	103.9	+3.7%
	Glass	100 ml	100.1	104.8	+4.7%
		200 ml	101.0	100.4	-0.6%
	PE	100 ml	101.7	101.9	+0.2%
		200 ml	101.6	100.8	-0.8%
9.5	PVC	100 ml	99.5	100.1	+0.6%
		200 ml	100.0	100.4	+0.4%
	PP	100 ml	100.0	100.6	+0.6%
		200 ml	99.9	100.7	+0.8%
	Glass	100 ml	100.8	101.5	+0.7%
		200 ml	100.9	99.2	-1.70
	PE	100 ml	99.2	101.7	+2.5%
		200 ml	99.8	102.6	+2.8%

[0039] Just as in the case of impurities, we observe a tendency for a smaller loss of active principle (ibuprofen) to be obtained on increasing the pH, though to a varying extent depending on the container used. At pH of 6.5, loss of ibuprofen is increased in all cases. However, at pH 7.0 the loss of ibuprofen is already negligible in the samples packaged in glass and PE, whereas it is still significant in PP and, especially, PVC. At pH 7.5 the loss of ibuprofen is now only significant in PVC, and for pH greater than or equal to 8.0 the loss is not significant in any container.

[0040] On its side, the experimental tests carried out on the compositions produced according to the teachings of the DE document produced the following results:

pH	Material	Volume	Ibuprofen content % on 4 mg/ml (before autoclaving)	Ibuprofen content % on 4 mg/ml (after autoclaving)	Variation in the ibuprofen content (%)
7.0	PVC	100 ml	90.5	72.0	-20.4%
	PP	100 ml	96.6	75.7	-21.6%
	Vidrio	100 ml	96.3	88.2	-8.4%
	PE	100 ml	95.4	91.7	-3.9%
7.8	PVC	100 ml	93.9	78.4	-16.5%
	PP	100ml	95.3	81.7	-14.3%
	Vidrio	100 ml	94.2	89.1	-5.4%
	PE	100 ml	94.7	92.2	-2.6%
8.2	PVC	100 ml	94.8	85.3	-10.0%
	PP	100 ml	99.1	94.2	-4.9%
	Vidrio	100 ml	98.4	94.4	-4.1%
	PE	100 ml	98.6	94.7	-3.9%
9.0	PVC	100 ml	99.3	88.2	-11.2%
	PP	100 ml	99.6	91.0	-8.6%
	Vidrio	100 ml	99.9	81.1	-18.8%
	PE	100 ml	99.8	94.4	-5.4%

[0041] As can be observed, in the compositions prepared according to the teachings of the DE document an incomplete ibuprofen dissolution was frequently observed already before autoclaving, with initial ibuprofen contents below the required 95% minimum value, and in one case even hardly reaching 90%. These results are even worser after autoclaving since, following this thermal treatment, in no case the required minimum ibuprofen content of 95% was reached, and in many cases loses higher than 5% were found. In conclusion, the compositions having an ibuprofen content of about 8 mg/ml and a trometamol content of about 6.05 mg/ml are not suitable for autoclaving and compositions so prepared may lose upon autoclaving up to 28% of the initial ibuprofen added, depending on the pH considered.

3) Investigation of the change in pH of the test formulations after autoclaving:

[0042] The pH of the test formulations was measured after packaging, either without autoclaving or after autoclaving, to evaluate the change in this parameter caused by said process. The results were as follows:

pH	Material	Volume	Before autoclaving	After autoclaving
6.5	PVC	100 ml	7.44	7.80
		200 ml	7.43	7.75
	PP	100 ml	7.47	7.58
		200 ml	7.44	7.58
	Glass	100 ml	6.93	6.90
		200 ml	6.83	6.92
	PE	100 ml	6.66	7.50
		200 ml	6.64	7.42

(continued)

pH	Material	Volume	Before autoclaving	After autoclaving
7.0	PVC	100 ml	7.91	8.03
		200 ml	7.89	8.01
	PP	100 ml	7.88	7.86
		200 ml	7.87	7.89
	Glass	100 ml	7.41	7.40
		200 ml	7.30	7.39
	PE	100 ml	7.25	7.58
		200 ml	7.26	7.54
7.5	PVC	100 ml	8.37	8.39
		200 ml	8.35	8.40
	PP	100 ml	8.34	8.34
		200 ml	8.38	8.34
	Glass	100 ml	7.85	7.84
		200 ml	7.86	7.86
	PE	100 ml	7.72	7.91
		200 ml	7.75	7.89
8	PVC	100 ml	8.74	8.72
		200 ml	8.73	8.72
	PP	100 ml	8.71	8.73
		200 ml	8.71	8.74
	Glass	100 ml	8.31	8.28
		200 ml	8.31	8.32
	PE	100 ml	8.22	8.29
		200 ml	8.21	8.28
8.5	PVC	100 ml	9.12	9.15
		200 ml	9.11	9.16
	PP	100 ml	9.11	9.16
		200 ml	9.06	9.11
	Glass	100 ml	8.70	8.77
		200 ml	8.73	8.79
	PE	100 ml	8.87	8.57
		200 ml	8.82	8.56

(continued)

pH	Material	Volume	Before autoclaving	After autoclaving
9.0	PVC	100 ml	9.42	9.38
		200 ml	9.44	9.38
	PP	100 ml	9.46	9.44
		200 ml	9.47	9.42
	Glass	100 ml	9.23	9.14
		200 ml	9.21	9.24
	PE	100 ml	9.18	8.95
		200 ml	9.16	8.97
9.5	PVC	100 ml	9.83	9.72
		200 ml	9.80	9.70
	PP	100 ml	9.76	9.64
		200 ml	9.77	9.67
	Glass	100 ml	9.62	9.64
		200 ml	9.67	9.65
	PE	100 ml	9.40	9.27
		200 ml	9.37	9.29

[0043] On comparing the formulations after packaging without autoclaving and autoclaved, it is seen that the effect is, once again, slightly different depending on the container used: In general, at pH=6.5 we observe a significant increase in pH after autoclaving, which is a clear indication of the degradation of some of the components of the formulation, giving rise to derivatives of an alkaline character. However, this increase in pH is very significant in the samples stored in PE, is less significant in the samples stored in PVC and PP, and is hardly observed at all in the samples stored in glass. Moreover, as the initial pH of the formulations tested is increased, this increase in pH after autoclaving gradually decreases, so that it is hardly observed at all at certain pH values depending on the container used: The formulations in which the samples in the different containers have a barely observable decrease in pH are:

- for glass, starting from pH = 6.5
- for PP, starting from pH = 7.0, and
- for PVC, starting from pH= 7.5,

whereas for PE said increase, although it is reduced to values of the order of 0.1 units of pH at pH values of about 9.5, can never be regarded as barely observable.

4) Investigation of sub-visible particles:

[0044] The sub-visible particles in the formulations were also measured before and after autoclaving. This investigation was performed by direct measurement of this parameter in the sub-visible particle counter. The specification according to the European Pharmacopoeia is as follows:

For 100 ml:

$\leq$ 6000 part./container $\geq$ 10μm
$\leq$ 600 part./container $\geq$ 25μm

For 200 ml:

$\leq$ 25 part./ml $\geq$ 10μm

≤ 3 part./ml ≥ 25μm

[0045] The results obtained in the formulations tested were as follows:

pH	Material	Volume	Without Autoclaving	Autoclaved
6.5	PVC	100 ml	556 part./bag ≥ 10μm 100 part./bag ≥ 25μm	1122 part./bag ≥ 10μm 67 part./bag ≥ 25μm
		200 ml	4 part./ml ≥ 10μm 0 part./ml ≥ 25μm	16 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	PP	100 ml	489 part./bag > 10μm 89 part./bag ≥ 25μm	300 part./bag ≥ 10μm 33 part./bag ≥ 25μm
		200 ml	4 part./ml ≥ 10μm 1 part./ml ≥ 25μm	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	Glass	100 ml	889 part./container ≥ 10μm 167 part./container ≥ 25μm	411 part./container ≥ 10μm 67 part./container ≥ 25μm
		200 ml	4 part./ml ≥ 10μm 1 part./ml ≥ 25μm	8 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	PE	100 ml	2544 part./container ≥ 10μm 67 part./container ≥ 25μm	2967 part./container ≥ 10μm 589 part./container ≥ 25μm
		200 ml	11 part./ml ≥ 10μm 1 part./ml ≥ 25μm	12 part./ml ≥ 10μm 1 part./ml ≥ 25μm
7	PVC	100 ml	533 part./bag ≥ 10μm 156 part./bag ≥ 25μm	411 part./bag ≥ 10μm 67 part./bag ≥ 25μm
		200 ml	6 part./ml ≥ 10μm 0 part./ml ≥ 25μm	5 part./ml ≥ 10μm 2 part./ml ≥ 25μm
	PP	100 ml	389 part./bag ≥ 10μm 78 part./bag ≥ 25μm	667 part./bag ≥ 10μm 33 part./bag ≥ 25μm
		200 ml	2 part./ml ≥ 10μm 1 part./ml ≥ 25μm	5 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	Glass	100 ml	467 part./container ≥ 10μm 78 part./container ≥ 25μm	922 part./container ≥ 10μm 89 part./container ≥ 25μm
		200 ml	9 part./ml ≥ 10μm 1 part./ml	4 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	PE	100 ml	1322 part./container ≥ 10μm 100 part./container ≥ 25μm	4733 part./container ≥ 10μm 500 part./container ≥ 25μm
		200 ml	15 part./ml ≥ 10μm 1 part./ml ≥ 25μm	15 part./ml ≥ 10μm 2 part./ml ≥ 25μm
7.5	PVC	100 ml	522 part./bag ≥ 10μm 67 part./bag ≥ 25μm	3189 part./bag ≥ 10μm 322 part./bag ≥ 25μm
		200 ml	7 part./ml ≥ 10μm 1 part./ml ≥ 25μm	10 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	PP	100 ml	456 part./bag ≥ 10μm 44 part./bag ≥ 25μm	933 part./bag ≥ 10μm 56 part./bag ≥ 25μm
		200 ml	3 part./ml ≥ 10μm 0 part./ml ≥ 25μm	4 part./ml ≥ 10μm 0 part./ml ≥ 25μm

(continued)

pH	Material	Volume	Without Autoclaving	Autoclaved
8	Glass	100 ml	911 part./container ≥ 10μm 133 part./container ≥ 25μm	156 part./container ≥ 10μm 11 part./container ≥ 25μm
		200 ml	6 part./ml ≥ 10μm 1 part./ml ≥ 25μm	3 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	PE	100 ml	2033 part./container ≥ 10μm 122 part./container ≥ 25μm	1022 part./container ≥ 10μm 56 part./container ≥ 25μm
		200 ml	23 part./ml ≥ 10μm 1 part./ml ≥ 25μm	22 part./ml ≥ 10μm 2 part./ml ≥ 25μm
	PVC	100 ml	500 part./bag ≥ 10μm 89 part./bag ≥ 25μm	544 part./bag 10μm 44 part./bag ≥ 25μm
		200 ml	3 part./ml ≥ 10μm 0 part./ml ≥ 25μm	13 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	PP	100 ml	400 part./bag ≥ 10μm 44 part./bag ≥ 25μm	222 part./bag ≥ 10μm 33 part./bag ≥ 25μm
		200 ml	6 part./ml ≥ 10μm 0 part./ml ≥ 25μm	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	Glass	100 ml	2367 part./container ≥ 10μm 111 part./container ≥ 25μm	444 part./container ≥ 10μm 22 part./container ≥ 25μm
		200 ml	6 part./ml ≥ 10μm 1 part./ml ≥ 25μm	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm
8.5	PE	100 ml	667 part./container ≥ 10μm 56 part./container ≥ 25μm	2300 part./container ≥ 10μm 22 part./container ≥ 25μm
		200 ml	13 part./ml ≥ 10μm 2 part./ml 25μm	12 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	PVC	100 ml	444 part./bag ≥ 10μm 33 part./bag ≥ 25μm	978 part./bag ≥ 10μm 44 part./bag ≥ 25μm
		200 ml	5 part./ml ≥ 10μm 1 part./ml ≥ 25μm	7 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	PP	100 ml	222 part./bag ≥ 10μm 67 part./bag ≥ 25μm	467 part./bag ≥ 10μm 44 part./bag ≥ 25μm
		200 ml	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm	4 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	Glass	100 ml	978 part./container ≥ 10μm 111 part./container ≥ 25μm	267 part./container ≥ 10μm 44 part./container ≥ 25μm
		200 ml	6 part./ml ≥ 10μm 0 part./ml ≥ 25μm	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	PE	100 ml	722 part./container ≥ 10μm 100 part./container ≥ 25μm	1656 part./container ≥ 10μm 167 part./container ≥ 25μm
		200 ml	4 part./ml ≥ 10μm 1 part./ml ≥ 25μm	9 part./ml ≥ 10μm 1 part./ml ≥ 25μm

(continued)

pH	Material	Volume	Without Autoclaving	Autoclaved
9	PVC	100 ml	344 part./bag ≥ 10μm 89 part./bag ≥ 25μm	2689 part./bag ≥ 10μm 100 part./bag ≥ 25μm
		200 ml	4 part. /ml ≥ 10μm 0 part./ml ≥ 25μm	37 part./ml ≥ 10μm 1 part./ml ≥ 25μm
	PP	100 ml	667 part./bag ≥ 10μm 89 part./bag ≥ 25μm	1200 part./bag ≥ 10μm 56 part./bag ≥ 25μm
		200 ml	3 part./ml ≥ 10μm 0 part./ml ≥ 25μm	16 part./ml ≥ 10μm 2 part./ml ≥ 25μm
	Glass	100 ml	800 part./container ≥ 10μm 67 part./container ≥ 25μm	278 part./container ≥ 10μm 44 part./container ≥ 25μm
		200 ml	3 part./ml ≥ 10μm 0 part./ml ≥ 25μm	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	PE	100 ml	1978 part./container ≥ 10μm 211 part./container ≥ 25μm	2722 part./container ≥ 10μm 4 part./container ≥ 25μm
		200 ml	8 part./ml ≥ 10μm 1 part./ml ≥ 25μm	14 part./ml ≥ 10μm 2 part./ml ≥ 25μm
9.5	PVC	100 ml	611 part./bag ≥ 10μm 133 part./bag ≥ 25μm	28756 part./bag ≥ 10μm 4456 part. /bag≥25μm(*1)
		200 ml	16 part./ml ≥ 10μm 2 part./ml ≥ 25μm	721 part./ml ≥ 10μm 119 part./ml ≥ 25μm(*1)
	PP	100 ml	789 part./bag ≥ 10μm 100 part./bag ≥ 25μm	3878 part./bag ≥ 10μm 878 part./bag ≥ 25μm(*1)
		200 ml	3 part./ml ≥ 10μm 0 part./ml ≥ 25μm	18 part./ml ≥ 10μm 3 part. /ml ≥ 25μm(*1)
	Glass	100 ml	989 part./container ≥ 10μm 44 part./container ≥ 25μm	389 part./container ≥ 10μm 0 part./container ≥ 25μm
		200 ml	6 part./ml ≥ 10μm 1 part./ml ≥ 25μm	2 part./ml ≥ 10μm 0 part./ml ≥ 25μm
	PE	100 ml	1189 part./container ≥ 10μm 144 part./container ≥ 25μm	1911 part./container ≥ 10μm 111 part./container ≥ 25μm
		200 ml	10 part./ml ≥ 10μm 1 part../ml ≥ 25μm	14 part./ml ≥ 10μm 2 part./ml ≥ 25μm
(*1) A large amount of particles and filaments, visible in suspension, appears.				

[0046] It can be seen in this table that when the formulations are packaged in glass containers, in all cases the level of sub-visible particles is within the specifications, and with a slight tendency to exhibit a lower level of said particles on increasing the pH of the formulation, particularly in the case of the formulations that are autoclaved, although it is in any case concluded that for glass the acceptable pH range of the formulations comprises all the pH values tested, i.e. from 6.5 to 9.5.

[0047] However, in the case of formulations packaged in PP, in PVC and in PE, high pH levels (pH=9.5) give rise to an increased amount of sub-visible particles in the case of the autoclaved formulations, particularly in the case of PVC, and to a smaller extent PP and PE. Therefore in the case of these materials, the acceptable pH range of the formulations would comprise from 6.5 to 9.0.

[0048] Accordingly, it can be concluded that although the formulations of ibuprofen for injection according to the invention can be used, in general, between pH of 7.0 and 9.5, the most preferred embodiments of the invention would

be, for example, the following:

- When the formulation is in containers of glass: pH of the formulation between 8.0 and 9.0 and most preferably about 8.5;
- When the formulation is in containers of PE: pH of the formulation between more preferably 8.0 and 9.0 and most preferably about 8.5;
- When the formulation is in containers of PP: pH of the formulation between 8.0 and 9.0, and most preferably about 8.5;
- When the formulation is in containers of PVC: pH of the formulation between 8.0 and 9.0, and more preferably about 8.5.

[0049] These formulations are able to maintain the levels of concentration of the active principle within acceptable values after autoclaving, with an acceptable variation of other important parameters of the compositions such as increase in content of impurities, change in pH or increase in sub-visible particles when the formulations of the invention are submitted to autoclaving.

Claims

1. Pharmaceutical composition of ibuprofen for injection comprising an aqueous solution of ibuprofen and trometamol, wherein the concentration of ibuprofen is between 2 and 6 mg/ml, the concentration of trometamol is between 1.8 and 5.8 mg/ml, and the pH is between 8.0 and 9.0.

2. Pharmaceutical composition of ibuprofen for injection according to Claim 1, wherein the concentration of ibuprofen is about 4 mg/ml.

3. Pharmaceutical composition according to Claims 1 or 2, wherein the concentration of trometamol is approximately 3.8 mg/ml.

4. Pharmaceutical compositon according to any one of previous claims 1 to 3 which is sterilizable by heat by autoclaving at a temperature between 110°C and 130°C for a time between 2 and 190 minutes.

5. Pharmaceutical composition according to Claim 4, wherein the composition is sterilizable by heat by autoclaving at a temperature of 121°C for 15 minutes.

6. Pharmaceutical composition of ibuprofen for injection according to any one of previous Claims 1 to 5 wherein, when the composition is provided in containers of glass, the pH is between 8.0 and 9.0.

7. Pharmaceutical composition of ibuprofen for injection according to any one of previous Claims 1 to 5, wherein, when the composition is provided in containers of polyethylene, the pH is between 8.0 and 9.0.

8. Pharmaceutical composition of ibuprofen for injection according to any one of previous Claims 1 to 5 wherein, when the composition is provided in containers of polypropylene, the pH is between 8.0 and 9.0.

9. Pharmaceutical composition of ibuprofen for injection according to any one of previous Claims 1 to 5, wherein when the composition is provided in containers of PVC, the pH is between 8.0 and 9.0.

10. Pharmaceutical composition according to any one of the preceding claims, wherein the pH is about 8.5.

11. Pharmaceutical composition according to any one of the preceding claims, further comprising a salt in the necessary amount for endowing the composition with an osmolality of about 300 mOsm/kg.

12. Pharmaceutical composition according to Claim 11, wherein the salt is NaCl at a concentration of approximately 7.7 mg/ml.

13. Composition according to any one of Claims 1 to 12 for use in the treatment of pain, inflammation or fever.

14. Composition according to Claim 13, which is provided in containers of 100 ml or 200 ml.

15. Use of a pharmaceutical composition according to any one of Claims 1 to 12 in the manufacture of a medicament for the treatment of pain, inflammation or fever.

Patentansprüche

1. Pharmazeutische Zusammensetzung aus Ibuprofen zur Injektion, die eine wässrige Lösung aus Ibuprofen und Trometamol umfasst, wobei die Konzentration von Ibuprofen zwischen 2 und 6 mg/ml, die Konzentration von Trometamol zwischen 1,8 und 5,8 mg/ml und der pH-Wert zwischen 8,0 und 9,0 liegt.

2. Pharmazeutische Zusammensetzung aus Ibuprofen zur Injektion nach Anspruch 1, wobei die Konzentration von Ibuprofen etwa 4 mg/ml beträgt.

3. Pharmazeutische Zusammensetzung nach Anspruch 1 oder 2, wobei die Konzentration von Trometamol etwa 3,8 mg/ml beträgt.

4. Pharmazeutische Zusammensetzung nach irgendeinem der vorangehenden Ansprüche 1 bis 3, die durch Autoklavieren bei einer Temperatur von 110ºC bis 130ºC für einen Zeitraum von 2 bis 190 Minuten hitzesterilisierbar ist.

5. Pharmazeutische Zusammensetzung nach Anspruch 4, wobei die Zusammensetzung durch Autoklavieren bei einer Temperatur von 121ºC für einen Zeitraum von 15 Minuten hitzesterilisierbar ist.

6. Pharmazeutische Zusammensetzung aus Ibuprofen zur Injektion nach irgendeinem der vorangehenden Ansprüche 1 bis 5, wobei der pH-Wert zwischen 8,0 und 9,0 liegt, wenn die Zusammensetzung in Glasbehältern bereitgestellt wird.

7. Pharmazeutische Zusammensetzung aus Ibuprofen zur Injektion nach irgendeinem der vorangehenden Ansprüche 1 bis 5, wobei der pH-Wert zwischen 8,0 und 9,0 liegt, wenn die Zusammensetzung in Polyethylenbehältern bereitgestellt wird.

8. Pharmazeutische Zusammensetzung aus Ibuprofen zur Injektion nach irgendeinem der vorangehenden Ansprüche 1 bis 5, wobei der pH-Wert zwischen 8,0 und 9,0 liegt, wenn die Zusammensetzung in Polypropylenbehältern bereitgestellt wird.

9. Pharmazeutische Zusammensetzung aus Ibuprofen zur Injektion nach irgendeinem der vorangehenden Ansprüche 1 bis 5, wobei der pH-Wert zwischen 8,0 und 9,0 liegt, wenn die Zusammensetzung in PVC-Behältern bereitgestellt wird.

10. Pharmazeutische Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, wobei der pH-Wert etwa 8,5 beträgt.

11. Pharmazeutische Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, die weiterhin ein Salz in der notwendigen Menge umfasst, um der Zusammensetzung eine Osmolalität von etwa 300 mOsm/kg zu verleihen.

12. Pharmazeutische Zusammensetzung nach Anspruch 11, wobei das Salz NaCl in einer Konzentration von etwa 7,7 mg/ml ist.

13. Zusammensetzung nach irgendeinem der Ansprüche 1 bis 12 für die Verwendung bei der Behandlung von Schmerzen, Entzündungen oder Fieber.

14. Zusammensetzung nach Anspruch 13, die in Behältern von 100 ml oder 200 ml bereitgestellt wird.

15. Verwendung einer pharmazeutischen Zusammensetzung nach irgendeinem der Ansprüche 1 bis 12 bei der Herstellung eines Medikaments zur Behandlung von Schmerzen, Entzündungen oder Fieber.

Revendications

1. Composition pharmaceutique d'ibuprofène pour injection comprenant une solution aqueuse d'ibuprofène et de trométamol, dans laquelle la concentration d'ibuprofène est comprise entre 2 et 6 mg/ml, la concentration de trométamol est comprise entre 1,8 et 5,8 mg/ml, et le pH est compris entre 8,0 et 9,0.

2. Composition pharmaceutique d'ibuprofène pour injection selon la revendication 1, dans laquelle la concentration d'ibuprofène est d'environ 4 mg/ml.

3. Composition pharmaceutique selon les revendications 1 ou 2, dans laquelle la concentration de trométamol est approximativement de 3,8 mg/ml.

4. Composition pharmaceutique selon n'importe laquelle des revendications précédentes 1 à 3 qui peut être stérilisée à l'autoclave en chauffant à une température comprise entre 110° C et 130° C pendant une durée comprise entre 2 et 190 minutes.

5. Composition pharmaceutique selon la revendication 4, dans laquelle la composition peut être stérilisée à l'autoclave en chauffant à une température de 121°C pendant 15 minutes.

6. Composition pharmaceutique d'ibuprofène pour injection selon n'importe laquelle des revendications précédentes 1 à 5, dans laquelle, lorsque la composition est fournie dans des récipients en verre, le pH est compris entre 8,0 et 9,0.

7. Composition pharmaceutique d'ibuprofène pour injection selon n'importe laquelle des revendications précédentes 1 à 5, dans laquelle, lorsque la composition est fournie dans des récipients en polyéthylène, le pH est compris entre 8,0 et 9,0.

8. Composition pharmaceutique d'ibuprofène pour injection selon n'importe laquelle des revendications précédentes 1 à 5, dans laquelle, lorsque la composition est fournie dans des récipients en polypropylène, le pH est compris entre 8,0 et 9,0.

9. Composition pharmaceutique d'ibuprofène pour injection selon n'importe laquelle des revendications précédentes 1 à 5, dans laquelle, lorsque la composition est fournie dans des récipients en PVC, le pH est compris entre 8,0 et 9,0.

10. Composition pharmaceutique selon n'importe laquelle des revendications précédentes, dans laquelle le pH est d'environ 8,5.

11. Composition pharmaceutique selon n'importe laquelle des revendications précédentes, comprenant en outre un sel dans la quantité nécessaire pour doter la composition d'une osmolalité d'environ 300 mOsm/kg.

12. Composition pharmaceutique selon la revendication 11, dans laquelle le sel est du NaCl à une concentration de 7,7 mg/ml.

13. Composition selon n'importe laquelle des revendications 1 à 12 à utiliser dans le traitement de la douleur, de l'inflammation ou de la fièvre.

14. Composition selon la revendication 13, qui est fournie dans des récipients de 100 ml ou de 200 ml.

15. Utilisation d'une composition pharmaceutique selon n'importe laquelle des revendications 1 à 12 dans la fabrication d'un médicament pour le traitement de la douleur, de l'inflammation ou de la fièvre.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 03039532 A1 **[0006]**
- WO 2005065674 A1 **[0006]**
- DE 19912436 A1 **[0008] [0017]**
- WO 0056325 A **[0008]**